Ladarixin With Sotorasib in Advanced NSCLC
NCT05815173
This study is recruiting at 6 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- NYU Langone Health
- Last updated on ClinicalTrials.gov
- December 30, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 6
- NYU Langone Health · Garden City, NY
- NYU Langone Health · Mineola, NY
- NYU Langone Health · New Hyde Park, NY
- NYU Langone Health · New York, NY
- NYU Langone Health · New York, NY
- NYU Langone Health · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.